Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder

American Journal of Psychiatry

Volumn 162, Issue 1, 2005, Pages 151-161

  Foa, Edna B ^a   Liebowitz, Michael R ^b   Kozak, Michael J ^b   Davies, Sharon ^b   Campeas, Rafael ^b   Franklin, Martin E ^b   Huppert, Jonathan D ^b   Kjernisted, Kevin ^b   Rowan, Vivienne ^b   Schmidt, Andrew B ^b   Simpson, H Blair ^b   Tu, Xin ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; EXPOSURE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STEREOTYPY; SWEATING; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR THERAPY; CLOMIPRAMINE; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PLACEBOS; SOFTWARE DESIGN; TREATMENT OUTCOME;

EID: 19944426181     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.1.151     Document Type: Article

References (49)

1. Myers J, Weissman M, Tischler G, Holzer CE, Leaf PJ, Orvaschel H, Anthony JC, Boyd JH, Burke JD, Kramer M, Stoltzman R: Six-month prevalence of psychiatric disorders in three communities: 1980-1982. Arch Gen Psychiatry 1984; 41:959-967
2. Karno M, Golding JM, Sorenson SB, Burnam MA: The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45:1094-1099
3. Robins LN, Helzer JE, Weissman MM, Orvaschel H: Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41:949-958
4. Rasmussen SA, Tsuang MT: Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry 1986; 143:317-322
5. Koran LM, Thienemann ML, Davenport R: Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry 1996; 153:783-788
6. Leon AC, Portera L, Weisman MM: The social costs of anxiety disorders. Br J Psychiatry 1995; 166(suppl 27):19-22
7. Riggs DS, Hiss H, Foa EB: Marital distress and the treatment of obsessive-compulsive disorder. Behav Ther 1992; 23:585-597
8. Meyer V: Modification of expectations in cases with obsessional rituals. Behav Res Ther 1966; 4:273-280
9. March JS, Frances A, Carpenter D, Kahn D: The Expert Consensus Guidelines Series: Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997; 58(suppl 4)
10. Clomipramine Collaborative Group: Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48:730-738
11. Greist JH, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52:289-295
12. Goodman WK, Price LH, Rassmussen SA, Delgado PL, Heninger GR, Charney DS: Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989; 46:36-44
13. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB, Paroxetine OCD Study Group: Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003; 64:1113-1121
14. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA: A multicenter investigation of fixed dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51:559-567
15. Montgomery SA, Kasper S, Stein DJ, Hedegaard K, Bang LOM: Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16:75-86
16. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ: Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Outcomes Manage 1998; 136:205-216
17. Ackerman D, Greenland S: Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002; 22:309-317
18. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R: Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 1980; 136:1-25
19. Marks IM, Lelliott P, Basoglu M, Noshirvani H, Monteiro W, Cohen D, Kasvikis Y: Clomipramine, self-exposure, and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988; 152:522-534
20. Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM, Douge R, Cialdella P: A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990; 5:17-30
21. Hohagen F, Winkelmann G, Rasche-Rauchle H, Hand I, Koenig A, Muenchau N, Hiss H, Geiger-Kabisch C, Kaeppler C, Schramm P, Rey E, Aldenhoff J, Berger M: Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. Br J Psychiatry 1998; 173:71-78
22. van Balkom AJLM, de Haan E, van Oppen P, Spinhoven P, Hoogduin KAL, van Dyck R: Cognitive and behavioral therapies alone and in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998; 186:492-499
23. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research, 1996
24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry 1989; 46:1012-1016
25. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011
26. Goodman WK, Price LH: Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am 1992; 15:861-869
27. Hiss H, Foa EB, Kozak MJ: Relapse prevention program for treatment of obsessive-compulsive disorder. J Consult Clin Psychol 1994; 62:801-808
28. Insel TR, Donnelly LF, Lalakea ML, Alterman IS, Murphy DL: Neurological and neuropsychological studies of patients with obsessive-compulsive disorder. Biol Psychiatry 1983; 18:741-751
29. Murphy DL, Pickar D, Alterman IS: Methods for the quantitative assessment of depressive and manic behavior, in The Behavior of Psychiatric Patients. Edited by Burdock EI, Sudilovsky A, Gershon S. New York, Marcel Dekker, 1982, pp 355-392
30. Kim SW, Dysken MW, Kuskowski M: The Symptom Checklist-90 obsessive compulsive subscale: a reliability and validity study. Psychiatr Res 1992; 41:37-44
31. Black DW, Kelly M, Myers C, Noyes R Jr: Tritiated imipramine binding in obsessive-compulsive volunteers and psychiatrically normal controls. Biol Psychiatry 1990; 27:319-327
32. Taylor S: Assessment of obsessions and compulsions: reliability, validity, and sensitivity to treatment effects. Clin Psychol Rev 1995; 15:261-296
33. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
34. Hedlund J, Vieweg B: The Hamilton Rating Scale for Depression: a comprehensive review. J Operational Psychiatry 1979; 10:149-165
35. Kozak MJ, Foa EB: Mastery of Obsessive-Compulsive Disorder: A Cognitive Behavioral Approach. San Antonio, Tex, Graywind Publications, 1997
36. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT: Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993; 50:739-750
37. Nich C, Carroll K: Now you see it, now you don't: a comparison of traditional versus random-effects regression models in the analysis of longitudinal follow-up data from a clinical trial. J Consult Clin Psychol 1997; 65:252-261
38. Fals-Stewart W, Marks AP, Schafer J: A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder. J Nerv Ment Dis 1993; 181:189-193
39. Lindsay M, Crino R, Andrews G: Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Br J Psychiatry 1997; 171:135-139
40. Marks IM, Hodgson R, Rachman S: Treatment of chronic obsessive-compulsive neurosis by in-vivo exposure: a two-year follow-up and issues in treatment. Br J Psychiatry 1975; 127:349-364
41. Klein DF: Preventing hung juries about therapy studies. J Consult Clin Psychol 1996; 64:81-87
42. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, Woods SW, Gorman JM: Pretreatment attrition in a comparative treatment outcome study on panic disorder. Am J Psychiatry 1998; 155:43-47
43. Huppert JD, Franklin ME, Foa EB, Davidson JR: Study refusal and exclusion from a randomized treatment study of generalized social phobia. J Anxiety Disord 2003; 17:683-693
44. Barlow DH, Gorman JM, Shear MK, Woods SW: Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283:2529-2536
45. Franklin ME, Abramowitz JS, Kozak MJ, Levitt JT, Foa EB: Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Consult Clin Psychol 2000; 68:594-602
46. DeVeaugh-Geiss J, Landau P, Katz R: Treatment of OCD with clomipramine. Psychiatr Annals 1989; 19:97-101
47. Abramowitz JS, Franklin ME, Street GP, Kozak MJ, Foa EB: Effects of comorbid depression on response to treatment for obsessive-compulsive disorder. Behav Ther 2000; 31:517-528
48. Abramowitz JS: Variants of exposure and response prevention in the treatment of obsessive-compulsive disorder: a meta-analysis. Behav Ther 1996; 27:583-600
49. Abramowitz JS, Foa EB, Franklin ME: Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol 2003; 71:394-398